About Us
Nanophysics & Beyond
Curadigm
The Management
Healthcare Professionals
Scientific Publications
Patients
Patient Engagement
Investors
Corporate Presentation
Financial Calendar
Regulated Information
SEC Filings
Annual General Meetings
Shareholder Corner
Press Releases
Congresses & Events
Nanotalks
NBTXR3 Development
Our Expert Videos
Nanoblog
From Curie to Nano
Contact & Newsletter
Medical Device Vigilance – Pharmacovigilance
Medical Information
Join Us
Nous vous informons que ce site est conforme à la législation française actuelle sur les dispositifs médicaux.
Continuer
Rester sur la page
Financial | Nanobiotix Revenue Q2 2015
Scientific Clinical | Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3
1 July 2015
Financial | Nanobiotix Half Year Results for the period ended 30 June 2015
27 August 2015
Financial | Nanobiotix Revenue Q2 2015
Published by
Candice Teo
on
15 July 2015
Download pdf
No translations available for this page
